Remus Pharmaceuticals Ltd
Incorporated in 2015, Remus Pharma Ltd is in the business of trading and export of API and Finished Formulations and in Technical consultancy services[1]
- Market Cap ₹ 869 Cr.
- Current Price ₹ 738
- High / Low ₹ 983 / 580
- Stock P/E 23.5
- Book Value ₹ 298
- Dividend Yield 0.14 %
- ROCE 16.8 %
- ROE 12.2 %
- Face Value ₹ 10.0
Pros
- Company is almost debt free.
- Debtor days have improved from 107 to 59.8 days.
Cons
- Company has a low return on equity of 13.0% over last 3 years.
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Healthcare Healthcare Pharmaceuticals & Biotechnology Pharmaceuticals
Part of Nifty SME Emerge
Half Yearly Results
Consolidated Figures in Rs. Crores / View Standalone
Profit & Loss
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|
| 213 | 620 | 854 | |
| 184 | 575 | 797 | |
| Operating Profit | 29 | 46 | 57 |
| OPM % | 14% | 7% | 7% |
| 3 | 5 | 7 | |
| Interest | 0 | 1 | 1 |
| Depreciation | 1 | 2 | 3 |
| Profit before tax | 30 | 47 | 59 |
| Tax % | 20% | 19% | 22% |
| 24 | 38 | 46 | |
| EPS in Rs | 17.69 | 24.64 | 31.39 |
| Dividend Payout % | 4% | 3% | 2% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| TTM: | 38% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| TTM: | 28% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | 23% |
| 1 Year: | -20% |
| Return on Equity | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | 13% |
| Last Year: | 12% |
Balance Sheet
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|
| Equity Capital | 1 | 6 | 12 |
| Reserves | 156 | 250 | 339 |
| 14 | 23 | 27 | |
| 161 | 154 | 201 | |
| Total Liabilities | 333 | 433 | 579 |
| 14 | 16 | 18 | |
| CWIP | 0 | 0 | 8 |
| Investments | 105 | 186 | 275 |
| 215 | 231 | 277 | |
| Total Assets | 333 | 433 | 579 |
Cash Flows
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|
| 4 | 7 | 18 | |
| -9 | -11 | -15 | |
| 24 | 6 | 1 | |
| Net Cash Flow | 19 | 3 | 5 |
| Free Cash Flow | 3 | 3 | 4 |
| CFO/OP | 35% | 32% | 49% |
Ratios
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|
| Debtor Days | 198 | 64 | 60 |
| Inventory Days | 96 | 35 | 35 |
| Days Payable | 209 | 49 | 37 |
| Cash Conversion Cycle | 85 | 50 | 58 |
| Working Capital Days | 98 | 54 | 57 |
| ROCE % | 20% | 17% |
Insights
In beta| Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|
| Number of Registered Products products |
|
|||||
| Number of B2B Products products ・Standalone data |
||||||
| Number of B2C Products products ・Standalone data |
||||||
| B2C Revenue Share % of standalone revenue ・Standalone data |
||||||
| Dossiers Ready to File dossiers |
||||||
| LATAM Registered Products products |
||||||
| South East Asia Product Footprint products |
||||||
| Total Product Footprint in Semi-Regulated Markets products |
||||||
Extracted by Screener AI
Documents
Announcements
-
Certificate under SEBI (Depositories and Participants) Regulations, 2018
7 July 2026 - Filed Reconciliation of Share Capital Audit Report for quarter ended June 30, 2026.
-
Certificate under SEBI (Depositories and Participants) Regulations, 2018
7 July 2026 - Submitted Regulation 74(5) certificate for quarter ended June 30, 2026.
-
Quarterly Compliance Report on Corporate governance - within 21 days from the end of the quarter
7 July 2026 - Remus Pharmaceuticals says Regulation 27(2) corporate governance report filing is not applicable on NSE SME platform.
-
Outcome of Board Meeting
23 June 2026 - Board appoints Bhavik Shah as CFO and KMP effective July 9, 2026.
-
Appointment
23 June 2026 - Board appoints Bhavik Shah as CFO and KMP effective July 9, 2026.
Annual reports
Concalls
-
May 2026TranscriptPPT REC
-
Nov 2025Transcript PPT
-
Aug 2025TranscriptAI SummaryPPT
-
May 2025Transcript PPT
-
Nov 2024Transcript PPT REC
Business Overview:[1][2]
RPL and its group of companies specialize in marketing pharmaceutical products with expertise in Critical Care, Neurology, Cardiology, and Diabetic categories,
and recently getting off-patent molecules in various dosage forms and in complex generics. Company gets finished pharmaceutical formulations manufactured on loan license or contract manufacturing